HHS Public Access

Cost-Utility Analysis of Cancer Prevention, Treatment, and Control:

A Systematic Review

Aaron N. Winn, MPP[1,2], **Donatus U. Ekwueme, PhD**[3], **Gery P. Guy Jr., PhD**[3], and **Peter J. Neumann, ScD**[1]

[1]Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts

[2]Department of Health Policy and Management, University of North Carolina, Chapel Hill, North Carolina

[3]Division of Cancer Prevention and Control, CDC, Atlanta, Georgia

Abstract

Context—Substantial innovation related to cancer prevention and treatment has occurred in recent decades. However, these innovations have often come at a significant cost. Cost-utility analysis provides a useful framework to assess if the benefits from innovation are worth the additional cost. This systematic review on published cost-utility analyses related to cancer care is from 1988 through 2013. Analyses were conducted in 2013–2015.

Evidence acquisition—This review analyzed data from the Tufts Medical Center Cost-Effectiveness Analysis Registry (www.cearegistry.org), a comprehensive registry with detailed information on 4,339 original cost-utility analyses published in the peer-reviewed medical and economic literature through 2013.

Evidence synthesis—There were 721 cancer-related cost-utility analyses published from 1998 through 2013, with roughly 12% of studies focused on primary prevention and 17% focused on secondary prevention. The most often studied cancers were breast cancer (29%); colorectal cancer (11%); and prostate cancer (8%). The median reported incremental cost-effectiveness ratios (in 2014 U.S. dollars) were $25,000 for breast cancer, $24,000 for colorectal cancer, and $34,000 for prostate cancer.

Conclusions—The current evidence indicates that there are many interventions that are cost effective across cancer sites and levels of prevention. However, the results highlight the relatively small number of cancer cost-utility analyses devoted to primary prevention compared with secondary or tertiary prevention.

Address correspondence to: Peter Neumann, ScD, Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, 800 Washington Street, Boston MA 02111. pneumann@tuftsmedicalcenter.org.

Recent years have seen a rapid increase in new interventions in cancer prevention, diagnosis, and treatment.[1] Although these treatments often improve survival and quality of life,[1] in many cases they have also dramatically increased the cost of care. The National Cancer Institute estimates that costs of cancer care will increase by at least 27% from 2010 to 2020 simply due to an aging population.[2] The economic impact will be particularly acute in the Medicare program because of the program's limited ability to control service utilization and the increasing number of beneficiaries due to demographic changes.[3] For example, Medicare is legally required to cover cancer drugs that are considered a "medically accepted indication," which includes not only indications approved by the U.S. Food and Drug Administration but also indications supported by peer-reviewed publications and listed on medical compendia.[4] However, across Europe, economic evaluation is used extensively to ensure that adopted treatments provide good value for the money.[5] Articles about the rising costs of cancer care have increasingly appeared in the popular press and medical literature. [1,5–8] However, the situation is complicated by the fact that some cancer interventions are seen as "low value,"[4] whereas others may provide reasonable value by conventional economic benchmarks despite their high costs.

Economic evaluations of healthcare interventions provide a framework for assessing the value of new cancer screening, diagnosis, and treatments and are used to inform reimbursement and coverage decisions directly or indirectly in various countries,[5,9–12] including by some payers in the U.S.[13–15] Cost-effectiveness analysis (CEA) is a widely used economic evaluation technique to assess the value of healthcare interventions including cancer intervention programs.[16–19] CEA describes an intervention's impact in terms of an incremental cost-effectiveness ratio (ICER), which consists of its incremental costs divided by its incremental health benefits. To allow comparison of the relative efficiency of health-care interventions across a spectrum of conditions such as cancer, benefits are often measured using quality-adjusted life-years (QALYs), and the resulting CEA referred to as a cost-utility analysis (CUA), with a lower ICER corresponding to greater value.[20] QALYs capture both changes in the length and quality of life.

Application of CEA in oncology has been described in previous work,[16,21,22] summarizing CUAs prior to 2007.[8] From 2008 through 2013, the number of cancer-related CUA articles nearly quadrupled, with an increased focus on primary and secondary prevention. In this article, the authors update their previous work, concentrating on specific cancer sites, as well as on treatment and primary and secondary prevention.

Evidence Acquisition

The authors analyzed data from the Tufts Medical Center CEA Registry (www.cearegistry.org), a comprehensive registry with detailed information on 3,243 original CEAs published in the peer-reviewed medical and economic literature from 1988 through 2013. Details of the CEA Registry have been described elsewhere.[23] The review started with the first cancer-related CUA study conducted in 1988 and included all studies through 2013, the most recent year the CEA was updated when the study was conducted. The Tufts Medical Center CEA Registry contains original English-language CUA data that were obtained using MEDLINE, which searched for medical subject headings or text keywords

such as *quality-adjusted, quality-adjusted life year or QALY*, and *cost-utility analysis*. A total of 10,693 unique articles were identified, 4,013 of which were selected for full-text review based on an assessment of titles and abstracts and 4,339 included in the CEA registry (Figure 1). The authors excluded reviews, editorials, methodologic articles, and articles presenting health effects in units other than QALYs. Each article was reviewed with the aid of a standard data auditing form to determine its clarity, completeness, and health economic methodologic quality.[8] The quality assessment did not assess the accuracy of the clinical or modeling assumptions but rather if the authors correctly reported their results, stated assumptions, appropriately used utility weights, and characterized uncertainty. The form was developed based on a variety of sources, including the "checklist" for reporting reference-case CUAs recommended by the Panel on Cost-Effectiveness in Health and Medicine as well as other published guidelines.[9,20] Two readers, with master's- or doctoral-degree training in decision analysis and CEA, independently read and audited each article and then convened for a consensus audit to resolve discrepancies. The CEA Registry collected data on a wide variety of elements related to study sponsorship; the intervention and comparators under investigation; and the methods used to estimate and report costs, health effects, preference weights, modeling assumptions, and data limitations. The review included all studies that pertained to prevention, screening, and treatment of cancer, resulting in a total of 721 articles (Figure 1).

The primary outcomes of CUAs are the costs and QALYs. The cost-utility ratio reports the incremental change of the new intervention compared to the status quo. Because the CUAs in this review were conducted in numerous countries using different currencies for a period of >20 years, all non-U.S. currencies were converted into U.S. dollars using the appropriate foreign exchange factor for the relevant year, and all ratios inflated to 2014 U.S. dollars using the Consumer Price Index obtained from the Bureau of Labor Statistics available from www.bls.gov/cpi/data.htm.

The authors grouped studies pertaining to cancer into 18 broad subcategories by the type of cancer treated or prevented: breast; colorectal; cervix; prostate; lung; melanoma; hematologic cancers; gastrointestinal and hepatocellular; ovarian; brain; bladder; kidney; head and neck (the nose, sinuses, lips, oral cavity, salivary glands, throat, or larynx)[24]; uterus; pancreas; stomach; esophagus; and other cancers. Because some CUAs compared several interventions and included scenarios specific to patient subgroups or settings, a single study may have contributed more than one cost-utility ratio. In these situations, the ratio was weighted inversely according to the number of ratios reported in the article. That is, each ratio was assigned a statistical weight of $1/n$, where n was the number of ratios reported in an article.

The reported ratios were classified as most cost effective with values <$50,000, cost effective as $50,000–$100,000, and least cost effective as >$100,000 per QALY using willingness-to-pay threshold levels sometimes used by health economists. These threshold levels, though somewhat arbitrary, are based on conventions sometimes used in the U.S. to determine the cost effectiveness of an intervention.[20] Additionally, some ratios report cost savings and increasing health, which health economists refer to as dominant and the authors report as "cost saving," and other ratios report decreased health with increasing cost, which

health economists refer to as dominated and the authors report as "decreased health, increased costs." Chi-square tests were used to determine if categorical variables were statistically significant. Analyses were conducted in 2013–2015.

Interventions were classified as primary, secondary, or tertiary prevention.[25] Primary prevention is defined as the avoidance of the onset of disease by behavior modification or treatment. Examples of primary prevention could include chemoprevention for breast cancer, immunization, health education, and promotion of improved nutrition. Secondary prevention is defined as the avoidance or alleviation of disease by early detection and appropriate management. Examples include early clinical services and population screening to identify disease in asymptomatic people to enable timely treatment. Tertiary prevention is defined as being the treatment of an active disease and may include treatment to reduce complications and progression of established disease, for example, chemotherapy, surgical removal of a tumor, and radiation therapy.

Evidence Synthesis

The authors identified 721 original cancer-related CUAs in the CEA Registry. Appendix A (available online) provides summaries of the articles. The annual average number of cancer-related CUAs has increased markedly over time (Appendix Figure 1, available online). Moreover, the proportion of studies focused on primary and secondary prevention has increased from an average of four studies per year between 1998 and 2006 to 20 studies per year between 2007 and 2011 to 100 studies per year in 2012 and 2013. The top three studied diseases were breast cancer (29% of studies); colorectal cancer (11%); and prostate cancer (8%) (Table 2). Most studies pertained to the U.S. (40% of studies), followed by the United Kingdom (14%); Canada (9%); and the Netherlands (6%) (Table 1). The majority examined interventions for tertiary prevention (i.e., chemotherapy and post-diagnosis interventions, 71%), followed by secondary prevention (i.e., screening, 17%) and primary prevention (i.e., vaccination, 12%). Most published CUAs focused on pharmaceutical interventions (51%), followed by screening strategies (16%) and medical procedures (11%). Approximately 30% of studies were funded by pharmaceutical or device companies; 49% were funded by non-industry sources (i.e., government, foundations, and healthcare organizations); and 21% did not disclose their funding source (Table 1).

Overall, the 721 analyses presented 2,053 ICERs (of which 52% CUAs presented more than one ratio). The median reported cost-effectiveness ratios (in 2014 USD) for all cancer-related CUAs were $29,000, which is not significantly different between prevention categories (p=0.11). The median reported cost-effectiveness ratios (in 2014 USD) were $25,000 for breast cancer, $24,000 for colorectal cancer, $18,000 for cervical cancer, $37,000 for lung cancer, and $46,000 for melanoma (Table 2).

The reported cost-effectiveness ratios for screening interventions were generally in ranges conventionally thought of as most cost effective (<$50,000), except for prostate and kidney cancer, which was still found to be cost effective ($50,000–$100,000) (Appendix Table 1). The search identified 118 studies focused on screening interventions. For cancers recommended for screening by the U.S. Preventive Services Task Force at the time these

data were collected, the median ICER was $22,000 for breast, $15,000 for colorectal, and $28,000 for cervical. On the other hand, for cancers not recommended for screening at the time these data were collected, the median ICER was $30,000 for lung and $46,000 for melanoma. Few studies have examined the cost effectiveness of screening for melanoma.

The median ICER for interventions on primary cancer prevention programs was $23,000 (Table 2). For specific cancer sites, the median reported cost-effectiveness ratios were $48,000 for breast, cost saving for colorectal, $16,000 for cervical, $17,000 for lung, $120,000 for prostate, and $27,000 for melanoma. The distribution of ICERs by cancer site is presented in Table 3.

When the distribution of ICERs across all studies was assessed, 69% of ratios were < $50,000 or cost saving, 13% of ratios were between $50,000 and $100,000, and 21% of ratios were >$100,000 or decreased health and increased costs (Table 3). When the distribution of ICERs among primary prevention studies (Table 3) was examined, 78% were <$50,000 or cost saving, 12% were between $50,000 and $100,000, and 11% of ratios were >100,000 or decreased health and increased costs (Table 3). When looking at specific cancer sites among studies focused on primary prevention, the distribution of ICERs was similar across diseases, with the exception of prostate cancer (five studies), where at least half of the studies reported ICERs >$100,000.

There were more CUAs focused on tertiary (n=511) than secondary prevention (n=120) (Table 2). Though median ICERs were somewhat higher for secondary ($34,000) than for tertiary prevention ($29,000) (Table 2), the distribution was similar (Table 3), with 63% of studies reporting ICERs <$50,000 or cost saving, 31% reporting ICERs >$50,000, and 5%– 6% reporting decreased health and increased costs.

Discussion

The authors systematically reviewed all published cancer-related CUAs and updated their previous review. Since 2007, the number of cancer-related CUAs has almost quadrupled. This is likely due to payers worldwide (e.g., the National Institute for Health and Care Excellence in the United Kingdom) using data from economic evaluations to inform and support reimbursement decisions.[5,9,11,12] However, the focus of studies is similar to prior work.[8] Consistent with cancer-related CUAs published before 2008, this study found that researchers have devoted relatively little attention, as measured by publications, to the cost effectiveness of primary prevention compared with secondary or tertiary prevention.[8] As seen in work published before 2008, the majority of primary prevention studies were focused on cervical or breast cancer. For secondary prevention, there have been many CUAs focused on breast, colorectal, and cervical cancer, which is perhaps not surprising as these are cancer sites where screening is recommended. By contrast, few CUAs have examined screening for melanoma or lung cancer, areas in which screening are not recommended during our study period. However, in recent years, there has been movement to recommend low-dose computed tomography screening to detect lung cancer for specified group of individuals at high risk.[23] CUA studies published since 2013 on lung cancer have been

mixed, and have shown that the cost effectiveness of lung cancer screening is very sensitive to the assumptions on the effectiveness of screening.[24–26]

Numerous CUAs have examined tertiary prevention. Interestingly, the median and distribution of cancer cost-effectiveness ratios are similar to those found in other fields of health care.[26–29] Despite the fact that this updated review of cancer-related CUAs included many new expensive cancer drugs (e.g., cetuximab, bevacizumab, sunitinib, sorafenib), the distribution of ICERs has remained relatively constant over time. However, the cost-effectiveness literature may have been subject to publication bias in the sense that researchers and funders may selectively conduct cost-effectiveness studies and under-report unfavorable cost-effectiveness results.[27]

Limitations

This study has several limitations. First, it excluded CEAs that used measures of health outside of the QALY metric (e.g., cost per life-year gained or cost per 1 year of progression-free survival). Second, it only included English-language peer-reviewed publications indexed in MEDLINE. For example, health technology assessment reports, created by governmental bodies such as the National Institute for Clinical Excellence in the United Kingdom or other health technology assessment agencies, were excluded. However, the findings in some of these reports are complementary to the reviewed studies.[5,9,11,12] Third, this study did not assess the merits of clinical or modeling assumptions included in analyses or the quality of the data collected in studies conducted alongside clinical trials. Fourth, environmental, system, and policy interventions were not included in the reviewed studies. Fifth, this study only goes through 2013 and does not capture more recently published studies.

A final point worth emphasizing is that policy-makers using cost-utility information should examine carefully the individual studies and their interventions, comparators, and target populations when making decisions. The results presented here are summary data that provide a portrait of the literature to date. However, individual studies will investigate very different contexts (e.g., a colorectal cancer screening finding may be based on a comparison of colonoscopy versus fecal occult blood testing, whereas a treatment for stomach cancer result might be compared with diet and nutrition counseling). In recognition of the importance of economic evaluation, some countries have begun to use outcomes of economic analyses to inform coverage decisions, which has in turn contributed to restrictions in patients' access to new and expensive drugs.[9,10,12,30,31] Some have also acknowledged the unique circumstances of end-of-life care and have created mechanisms for coverage of cancer drugs or more flexible reimbursement criteria.[9,10,12] For example, in Canada or the United Kingdom, cancer drugs have been adopted at higher than average thresholds of cost effectiveness.[10,12] However, these higher thresholds appear to apply only to drugs and not to cancer screening.

Conclusions

In summary, the current evidence indicates that there are many interventions that are cost effective across cancer sites and stages of prevention. However, the results highlight the

relatively small number of cancer CUAs devoted to primary prevention compared with secondary or tertiary prevention.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

References

1. Meropol NJ, Schrag D, Smith TJ, et al. American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol. 2009; 27(23):3868–3874. http://dx.doi.org/10.1200/JCO.2009.23.1183. [PubMed: 19581533]

2. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010–2020. J Natl Cancer Inst. 2011; 103(2):117–128. http://dx.doi.org/10.1093/jnci/djq495. [PubMed: 21228314]

3. Lubitz J, Cai L, Kramarow E, Lentzner H. Health, life expectancy, and health care spending among the elderly. N Engl J Med. 2003; 349(11):1048–1055. http://dx.doi.org/10.1056/NEJMsa020614. [PubMed: 12968089]

4. Bach PB. Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med. 2009; 360(6):626–633. http://dx.doi.org/10.1056/NEJMhpr0807774. [PubMed: 19176475]

5. Drummond MF, Mason AR. European perspective on the costs and cost-effectiveness of cancer therapies. J Clin Oncol. 2007; 25(2):191–195. http://dx.doi.org/10.1200/JCO.2006.07.8956. [PubMed: 17210939]

6. Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst. 2009; 101(15):1044–1048. http://dx.doi.org/10.1093/jnci/djp177. [PubMed: 19564563]

7. Schnipper LE, Meropol NJ, Brock DW. Value and cancer care: toward an equitable future. Clin Cancer Res. 2010; 16(24):6004–6008. http://dx.doi.org/10.1158/1078-0432.CCR-10-1643. [PubMed: 21169254]

8. Greenberg D, Earle C, Fang CH, Eldar-Lissai A, Neumann PJ. When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology. J Natl Cancer Inst. 2010; 102(2):82–88. http://dx.doi.org/10.1093/jnci/djp472. [PubMed: 20056956]

9. Mason AR, Drummond MF. Public funding of new cancer drugs: is NICE getting nastier? Eur J Cancer. 2009; 45(7):1188–1192. http://dx.doi.org/10.1016/j.ejca.2008.11.040. [PubMed: 19138512]

10. Rocchi A, Menon D, Verma S, Miller E. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond. Value Health. 2008; 11(4):771–783. http://dx.doi.org/10.1111/j.1524-4733.2007.00298.x. [PubMed: 18179658]

11. Cairns J. Providing guidance to the NHS: The Scottish Medicines Consortium and the National Institute for Clinical Excellence compared. Health Pol. 2006; 76(2):134–143. http://dx.doi.org/10.1016/j.healthpol.2005.05.006.

12. Raftery JP. Paying for costly pharmaceuticals: regulation of new drugs in Australia, England and New Zealand. Med J Aust. 2008; 188(1):26–28. [PubMed: 18205559]

13. Neumann, PJ. Using Cost-Effectiveness Analysis to Improve Health Care: Opportunities and Barriers. New York: Oxford University Press; 2005. p. xiip. 209

14. Neumann PJ, Greenberg D. Is the United States ready for QALYs? Health Aff. 2009; 28(5):1366–1371. http://dx.doi.org/10.1377/hlthaff.28.5.1366.

15. Neumann PJ, Rosen AB, Weinstein MC. Medicare and cost-effectiveness analysis. N Engl J Med. 2005; 353(14):1516–1522. http://dx.doi.org/10.1056/NEJMsb050564. [PubMed: 16207857]

16. Neumann PJ, Thorat T, Shi J, Saret CJ, Cohen JT. The changing face of the cost-utility literature, 1990–2012. Value Health. 2015; 18(2):271–277. http://dx.doi.org/10.1016/j.jval.2014.12.002. [PubMed: 25773562]

17. Amin NP, Sher DJ, Konski AA. Systematic review of the cost effectiveness of radiation therapy for prostate cancer from 2003 to 2013. Appl Health Econ Health Policy. 2014; 12(4):391–408. http://dx.doi.org/10.1007/s40258-014-0106-9. [PubMed: 25022451]

18. Clegg A, Scott DA, Sidhu M, Hewitson P, Waugh N. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer. Health Technol Assess. 2001; 5(32):1–195. http://dx.doi.org/10.3310/hta5320.

19. Pignone M, Saha S, Hoerger T, Mandelblatt J. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2002; 137(2):96–104. http://dx.doi.org/10.7326/0003-4819-137-2-200207160-00007. [PubMed: 12118964]

20. U.S. Public Health Service Panel on Cost-effectiveness in Health and Medicine, United States. Cost-effectiveness in Health and Medicine: Report to the US Public Health Service. Washington, DC: Office of Disease Prevention and Health Promotion; 1996. p. xviii

21. Shih YC, Halpern MT. Economic evaluations of medical care interventions for cancer patients: how, why, and what does it mean? CA Cancer J Clin. 2008; 58(4):231–244. http://dx.doi.org/10.3322/CA.2008.0008. [PubMed: 18596196]

22. Grusenmeyer PA, Wong YN. Interpreting the economic literature in oncology. J Clin Oncol. 2007; 25(2):196–202. http://dx.doi.org/10.1200/JCO.2006.09.0738. [PubMed: 17210940]

23. Neumann PJ, Greenberg D, Olchanski NV, Stone PW, Rosen AB. Growth and quality of the cost-utility literature, 1976–2001. Value Health. 2005; 8(1):3–9. http://dx.doi.org/10.1111/j.1524-4733.2005.04010.x. [PubMed: 15841889]

24. National Cancer Institute. [Accessed May 16, 2014] Head and neck cancer. 2014. www.cancer.gov/cancertopics/types/head-and-neck

25. Martin, EA. Concise Medical Dictionary. 7. Oxford: Oxford University Press; 2007. p. 807

26. Wilson AW, Neumann PJ. The cost-effectiveness of biopharmaceuticals: A look at the evidence. MAbs. 2012; 4(2):281–288. http://dx.doi.org/10.4161/mabs.4.2.18812. [PubMed: 22377753]

27. Bell CM, Urbach DR, Ray JG, et al. Bias in published cost effectiveness studies: systematic review. BMJ. 2006; 332(7543):699–703. http://dx.doi.org/10.1136/bmj.38737.607558.80. [PubMed: 16495332]

28. Cohen JT, Neumann PJ, Weinstein MC. Does preventive care save money? Health economics and the presidential candidates. N Engl J Med. 2008; 358(7):661–663. http://dx.doi.org/10.1056/NEJMp0708558. [PubMed: 18272889]

29. Dalziel K, Segal L, Mortimer D. Review of Australian health economic evaluation—245 interventions: what can we say about cost effectiveness? Cost Eff Resour Alloc. 2008; 6:9. http://dx.doi.org/10.1186/1478-7547-6-9. [PubMed: 18489788]

30. Schrag D. The price tag on progress—chemotherapy for colorectal cancer. N Engl J Med. 2004; 351(4):317–319. http://dx.doi.org/10.1056/NEJMp048143. [PubMed: 15269308]

31. Shemer J. Year 2006 update of the National List of Health Services—an endless process. Isr Med Assoc J. 2006; 8(9):646–648. [PubMed: 17058419]

Appendix. Supplementary data

Supplementary data associated with this article can be found at http://dx.doi.org/10.1016/j.amepre.2015.08.009.

17,107 unique articles identified and screened

8,591 excluded after title and abstract screen

8,516 full-text articles assessed for eligibility

4,177 articles excluded

4,339 cost-utility analysis articles identified

3,618 articles excluded, not a cancer study

721 cancer focused studies

Figure 1.
PRISMA article identification and selection process.

Table 1

Characteristics of the Cancer Cost-Utility Analysis Literature

Characteristic	Number of studies (total N=721)	Percentage of studies, %
Country of study		
U.S.	287	40
United Kingdom	98	14
Canada	67	9
Netherlands	41	6
Australia	19	3
Italy	19	3
Sweden	18	2
France	17	2
China	15	2
Other	140	19
Intervention		
Pharmaceuticals	367	51
Screening	118	16
Medical procedure	82	11
Diagnostic	53	7
Other	62	9
Surgery	39	6
Level of prevention		
Primary	89	12
Secondary	121	17
Tertiary	511	71
Study sponsorship		
Non-industry	349	49
Industry	146	30
Not specified	226	21

Note: Intervention categories consist of the following: Pharmaceuticals = any drug or biotech product used for medical treatment or prevention; Screening = refers to measures that detect disease (or test for risk factors) before it is symptomatic; Medical Procedure = non-surgical, non-diagnostic procedures; Diagnostic = a method used to determine if and what type of disease is present; Surgery = invasive, cutting involved (e.g., transplantation, although bone marrow transplantation would be a medical procedure, appendectomy).

Table 2

Number of Studies and Incremental Cost-Effectiveness Ratios (ICERs) (2014 USD) by Cancer Types and Level of Prevention[a]

Cancer type	Overall		Primary prevention		Secondary prevention		Tertiary prevention	
	N	Median ICER	N	Median ICER	N	Median ICER	N	Median ICER
Overall	721	29,000	90	23,000	120	34,000	511	29,000
Breast	208	25,000	16	48,000	31	34,000	161	23,000
Colorectal	76	24,000	7	Cost-saving	15	14,000	54	26,000
Cervix	58	18,000	37	16,000	18	22,000	3	46,000
Prostate	59	34,000	5	120,000	8	85,500	46	29,000
Lung	58	37,000	4	17,000	8	61,000	46	38,000
Melanoma	14	46,000	4	27,000	2	66,500	8	77,000
Hematologic	57	34,000	—	—	—	—	57	34,000
Gastrointestinal and hepatocellular	44	44,000	5	34,000	15	40,000	24	47,000
Ovarian	20	26,500	2	Cost-saving	2	15,250	16	32,500
Brain	12	41,000	—	—	1	2,400,000	11	39,000
Bladder	5	Cost-saving	—	—	—	—	5	Cost-saving
Kidney	15	97,000	—	—	3	41,000	12	108,500
Head and neck	29	5,200	2	0	4	2,250	23	13,000
Uterus	1	Increases costs, decreases health	—	—	—	—	1	Increases costs, decreases health
Pancreas	12	66,000	1	20,000	1	86,000	10	77,000
Stomach	1	35,000	1	35,000	—	—	—	—
Esophagus	7	66,500	—	—	2	84,000	5	66,500

Cancer type	Overall		Primary prevention		Secondary prevention		Tertiary prevention	
	N	Median ICER	N	Median ICER	N	Median ICER	N	Median ICER
Other	45	39,000	6	63,000	10	38,000	29	39,000

[a] In each study, the estimated incremental cost-utility ratio was compared with the status quo (i.e., an older treatment regime, less effective screening technique, etc.).

Table 3

Distribution of Incremental Cost-Effectiveness Ratios for All Prevention Strategy Compared by Cancer Site at Different Willingness-to-Pay Thresholds[a]

Cancer type	Total (n)	Increases health, decreases costs, %	<50,000, %	50,000–100,000, %	>100,000, %	Decreases health, increases costs, %
All prevention stages						
Overall	721	15	54	13	15	6
Breast	208	12	55	12	17	4
Colorectal	76	22	43	11	15	8
Cervix	59	5	78	6	8	3
Prostate	59	10	45	13	20	12
Lung	58	11	43	17	25	4
Melanoma	14	60	19	21	0	0
Hematologic	57	5	56	21	13	5
Gastrointestinal and hepatocellular	44	7	48	24	20	2
Ovarian	20	20	51	14	9	6
Brain	12	17	47	3	27	6
Bladder	5	73	27	0	0	0
Kidney	15	23	8	23	36	10
Neck	29	24	48	5	9	13
Uterus	1	33	67	0	0	0
Pancreas	12	17	24	28	20	12
Stomach	1	100	0	0	0	0
Esophagus	7	21	25	18	18	18
Other	45	20	37	15	18	10
Primary prevention						
Overall	90	26	52	12	7	3
Breast	16	6	45	23	20	6
Colorectal	7	50	34	8	3	5
Cervix	37	5	85	4	5	2
Prostate	5	27	13	60	0	0

Cancer type	Total (n)	Increases health, decreases costs, %	<50,000, %	50,000–100,000, %	>100,000, %	Decreases health, increases costs, %
Lung	4	100	0	0	0	0
Melanoma	4	91	9	0	0	0
Gastrointestinal and hepatocellular	5	61	26	13	0	0
Ovarian	2	50	25	13	13	0
Neck	2	50	50	0	0	0
Stomach	1	100	0	0	0	0
Other	1	100	0	0	0	0
Secondary prevention						
Overall	120	11	52	14	18	5
Breast	31	6	52	15	25	3
Colorectal	15	8	59	9	11	12
Cervix	18	7	70	10	8	4
Prostate	8	13	31	9	31	16
Lung	8	4	40	28	28	0
Melanoma	2	50	50	0	0	0
Gastrointestinal and hepatocellular	15	2	54	19	23	1
Ovarian	2	88	13	0	0	0
Brain	1	60	40	0	0	0
Kidney	3	33	28	11	11	17
Neck	4	25	75	0	0	0
Pancreas	1	50	50	0	0	0
Esophagus	2	13	38	50	0	0
Other	10	10	46	13	22	10
Tertiary prevention						
Overall	511	16	46	15	16	6
Breast	161	14	57	10	15	4
Colorectal	54	22	40	12	17	8
Prostate	3	52	10	38	0	0
Lung	46	10	49	14	14	13

Cancer type	Total (*n*)	Increases health, decreases costs, %	<50,000, %	50,000–100,000, %	>100,000, %	Decreases health, increases costs, %
Melanoma	46	13	38	17	27	4
Hematologic	8	47	20	32	0	0
Gastrointestinal and hepatocellular	57	5	56	21	13	5
Ovarian	24	12	41	26	19	2
Brain	16	19	50	16	9	6
Bladder	11	19	52	3	23	3
Kidney	5	73	27	0	0	0
Neck	12	21	3	26	42	8
Uterus	23	22	48	7	11	13
Pancreas	1	33	67	0	0	0
Esophagus	10	20	13	34	19	14
Other	5	25	20	25	5	25

[a] In each study, the estimated incremental cost-utility ratio was compared with the status quo (i.e., an older treatment regime, less effective screening technique, etc.). Percentages may not add to 100 because of rounding.